Live News EQUITY FLASH L impact Oct 30, 2026, 01:10 PM UTC Alkermes Initiates Phase 2 Study of ALKS 7290 Alkermes said it has initiated a Phase 2 study of ALKS 7290 for major depressive disorder. ALKS SquawkNews Desk